Radiomultiomics: pioneering precision medicine for severe asthma
- PMID: 39572207
- DOI: 10.1183/13993003.01639-2024
Radiomultiomics: pioneering precision medicine for severe asthma
Conflict of interest statement
Conflict of interest: P.G. Woodruff reports grants from NIH (support for SPIROMICS, K24 award), COPD Foundation (support for SPIROMICS ancillary studies), and Genentech (support for a COVID-19 observational study), consultancy fees from Roche, Amgen and Sanofi, and participation on a data safety monitoring board or advisory board with NIH (CAUSE Pediatric asthma network). F. Polverino reports grants from NHLBI HL149744, Sanofi Pathway Grant PATH 118, Alpha 1 Foundation and Boehringer Ingelheim, consultancy fees from Sanofi/Regeneron, Amgen, AstraZeneca, Verona Pharma, Genentech and Chiesi, payment or honoraria for lectures, presentations, manuscript writing or educational events from Chiesi, support for attending meetings from Chiesi, patents pending (B cell therapy in emphysema), and a leadership role with ATS as RCMB programme committee chair.
Comment on
-
Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics.Eur Respir J. 2024 Nov 21;64(5):2400207. doi: 10.1183/13993003.00207-2024. Print 2024 Nov. Eur Respir J. 2024. PMID: 39401856 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources